Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer.


Journal

International braz j urol : official journal of the Brazilian Society of Urology
ISSN: 1677-6119
Titre abrégé: Int Braz J Urol
Pays: Brazil
ID NLM: 101158091

Informations de publication

Date de publication:
Historique:
received: 21 03 2018
accepted: 29 09 2018
pubmed: 7 12 2018
medline: 25 6 2019
entrez: 7 12 2018
Statut: ppublish

Résumé

To ascertain the opinions of North American genitourinary (GU) experts regarding inclusion of technologies such as prostate - specific membrane antigen (PSMA) and C - 11 choline positron emission tomography (PET) into routine practice. A survey was distributed to North American GU experts. Questions pertained to the role of PSMA and C - 11 PET in PCa management. Participants were categorized as "supporters" or "opponents" of incorporation of novel imaging techniques. Opinions were correlated with practice patterns. Response rate was 54% and we analyzed 42 radiation oncologist respondents. 17 participants (40%) have been in practice for > 20 years and 38 (90%) practice at an academic center. 24 (57%) were supporters of PSMA and 29 (69%) were supporters of C - 11. Supporters were more likely to treat pelvic nodes (88% vs. 56%, p < 01) and trended to be more likely to treat patients with moderate or extreme hypofractionation (58% vs. 28%, p = 065). Supporters trended to be more likely to offer brachytherapy boost (55% vs. 23%, p = 09), favor initial observation and early salvage over adjuvant radiation (77% vs. 55%, p = 09), and to consider themselves expert brachytherapists (69% vs. 39%, p = 09). There is a polarization among GU radiation oncology experts regarding novel imaging techniques. A correlation emerged between support of novel imaging and adoption of treatment approaches that are clinically superior or less expensive. Pre - existing biases among GU experts on national treatment - decision panels and leaders of cooperative group studies may affect the design of future studies and influence the adoption of these technologies in clinical practice.

Identifiants

pubmed: 30521167
doi: 10.1590/S1677-5538.IBJU.2018.0208
pii: IBJU20180208
pmc: PMC6442122
doi:

Substances chimiques

Antigens, Surface 0
Radiopharmaceuticals 0
Choline N91BDP6H0X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-31

Informations de copyright

Copyright® by the International Brazilian Journal of Urology.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Références

J Urol. 2004 Jun;171(6 Pt 1):2122-7
pubmed: 15126770
Radiother Oncol. 2007 Aug;84(2):114-20
pubmed: 17531335
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55
pubmed: 17531401
J Clin Oncol. 2007 Dec 1;25(34):5366-73
pubmed: 18048817
Curr Opin Urol. 2008 Jan;18(1):87-97
pubmed: 18090496
JAMA. 2008 Jun 18;299(23):2760-9
pubmed: 18560003
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Urology. 2009 Sep;74(3):643-7
pubmed: 19501891
Ann Nucl Med. 2011 Jul;25(6):414-8
pubmed: 21409348
BJU Int. 2012 Dec;110(11):1709-13
pubmed: 22934913
Clin Nucl Med. 2013 May;38(5):305-14
pubmed: 23486334
Radiother Oncol. 2014 Jan;110(1):45-54
pubmed: 23993400
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
J Urol. 2015 Dec;194(6):1624-30
pubmed: 26165583
Eur Urol. 2016 Jan;69(1):9-12
pubmed: 26189689
Prostate. 2015 Dec;75(16):1934-40
pubmed: 26356236
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69
pubmed: 26450693
Theranostics. 2015 Oct 18;5(12):1388-401
pubmed: 26681984
J Nucl Med. 2016 Apr;57(4):563-7
pubmed: 26769858
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30
pubmed: 27136743
Eur Urol. 2017 Jun;71(6):886-893
pubmed: 27484843
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):347-354
pubmed: 28068243
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39
pubmed: 29037965
Clin Genitourin Cancer. 2018 Apr;16(2):e323-e325
pubmed: 29174501

Auteurs

Kiri A Sandler (KA)

Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, CA, USA.

Shearwood McClelland (S)

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA.

Catherine Degnin (C)

Biostatistics Shared Resource, Oregon Health and Science University, Portland OR, USA.

Yiyi Chen (Y)

Biostatistics Shared Resource, Oregon Health and Science University, Portland OR, USA.

Timur Mitin (T)

Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH